Previous Close | 84.17 |
Open | 84.30 |
Bid | 84.43 x 1000 |
Ask | 84.72 x 1000 |
Day's Range | 83.98 - 84.95 |
52 Week Range | 62.07 - 87.87 |
Volume | |
Avg. Volume | 6,548,460 |
Market Cap | 105.314B |
Beta (5Y Monthly) | 0.20 |
PE Ratio (TTM) | 103.16 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (3.64%) |
Ex-Dividend Date | Sept 13, 2024 |
1y Target Est | N/A |
Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to
FOSTER CITY, Calif., October 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries
NORTHAMPTON, MA / ACCESSWIRE / September 25, 2024 / Gilead Sciences As a young gay professional, Terrell Parker spent several years working at the National Minority AIDS Council in Washington, D.C. during his 20s, advocating to help end the HIV epidemic ...